DBV Technologies (DBVT) Competitors $3.21 -0.01 (-0.31%) (As of 12/17/2024 05:56 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends DBVT vs. QTTB, PRQR, URGN, ELDN, ZNTL, ACRS, BNTC, ATAI, LFCR, and LXEOShould you be buying DBV Technologies stock or one of its competitors? The main competitors of DBV Technologies include Q32 Bio (QTTB), ProQR Therapeutics (PRQR), UroGen Pharma (URGN), Eledon Pharmaceuticals (ELDN), Zentalis Pharmaceuticals (ZNTL), Aclaris Therapeutics (ACRS), Benitec Biopharma (BNTC), Atai Life Sciences (ATAI), Lifecore Biomedical (LFCR), and Lexeo Therapeutics (LXEO). These companies are all part of the "pharmaceutical products" industry. DBV Technologies vs. Q32 Bio ProQR Therapeutics UroGen Pharma Eledon Pharmaceuticals Zentalis Pharmaceuticals Aclaris Therapeutics Benitec Biopharma Atai Life Sciences Lifecore Biomedical Lexeo Therapeutics DBV Technologies (NASDAQ:DBVT) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, community ranking, institutional ownership, valuation, analyst recommendations, risk and media sentiment. Is DBVT or QTTB more profitable? Q32 Bio has a net margin of 0.00% compared to DBV Technologies' net margin of -815.73%. DBV Technologies' return on equity of -106.07% beat Q32 Bio's return on equity.Company Net Margins Return on Equity Return on Assets DBV Technologies-815.73% -106.07% -76.17% Q32 Bio N/A -146.18%-54.49% Does the media favor DBVT or QTTB? In the previous week, Q32 Bio had 22 more articles in the media than DBV Technologies. MarketBeat recorded 33 mentions for Q32 Bio and 11 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 0.57 beat Q32 Bio's score of -0.04 indicating that DBV Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Q32 Bio 1 Very Positive mention(s) 6 Positive mention(s) 8 Neutral mention(s) 7 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate DBVT or QTTB? DBV Technologies presently has a consensus target price of $22.50, indicating a potential upside of 600.93%. Q32 Bio has a consensus target price of $29.86, indicating a potential upside of 770.47%. Given Q32 Bio's higher probable upside, analysts clearly believe Q32 Bio is more favorable than DBV Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DBV Technologies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Q32 Bio 0 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the MarketBeat Community prefer DBVT or QTTB? DBV Technologies received 392 more outperform votes than Q32 Bio when rated by MarketBeat users. However, 75.00% of users gave Q32 Bio an outperform vote while only 55.27% of users gave DBV Technologies an outperform vote. CompanyUnderperformOutperformDBV TechnologiesOutperform Votes40455.27% Underperform Votes32744.73% Q32 BioOutperform Votes1275.00% Underperform Votes425.00% Which has better valuation & earnings, DBVT or QTTB? DBV Technologies has higher revenue and earnings than Q32 Bio. DBV Technologies is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDBV Technologies$15.73M4.20-$72.73M-$4.50-0.71Q32 Bio-$6.65M-6.28-$112.96M-$14.25-0.24 Do institutionals & insiders believe in DBVT or QTTB? 71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 1.9% of DBV Technologies shares are owned by company insiders. Comparatively, 16.1% of Q32 Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, DBVT or QTTB? DBV Technologies has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Q32 Bio has a beta of -0.46, suggesting that its share price is 146% less volatile than the S&P 500. SummaryDBV Technologies beats Q32 Bio on 10 of the 18 factors compared between the two stocks. Ad Porter & CompanyForbes rich list released… #1 to be assassinated?Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get DBV Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DBVT vs. The Competition Export to ExcelMetricDBV TechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$66.03M$2.98B$5.18B$9.31BDividend YieldN/A1.85%4.78%4.06%P/E Ratio-0.7145.47130.2217.53Price / Sales4.20420.221,246.14139.51Price / CashN/A182.1341.2337.95Price / Book0.443.924.884.92Net Income-$72.73M-$42.03M$119.65M$225.78M7 Day Performance-2.43%-3.37%16.62%-1.56%1 Month Performance25.88%7.95%16.34%6.68%1 Year Performance-63.31%21.00%35.38%22.48% DBV Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DBVTDBV Technologies3.674 of 5 stars$3.21-0.3%$22.50+600.9%-61.2%$66.03M$15.73M-0.71106Analyst ForecastGap DownQTTBQ32 Bio2.8765 of 5 stars$23.59-9.0%$71.14+201.6%N/A$287.33M$1.16M-1.6539PRQRProQR Therapeutics2.3898 of 5 stars$3.50-1.7%$7.13+103.6%+36.7%$285.88M$7.05M0.00180URGNUroGen Pharma4.2968 of 5 stars$12.18-0.9%$43.70+258.8%-24.5%$285.62M$82.71M-3.90200ELDNEledon Pharmaceuticals3.2832 of 5 stars$4.74+3.0%$16.00+237.6%+196.1%$283.17MN/A-2.3310Short Interest ↓Positive NewsZNTLZentalis Pharmaceuticals2.544 of 5 stars$3.94+12.6%$10.00+153.8%-78.7%$280.76MN/A-1.57160ACRSAclaris Therapeutics3.8087 of 5 stars$3.93-0.3%$8.80+123.9%+222.8%$280.72M$31.25M0.0086BNTCBenitec Biopharma3.6558 of 5 stars$12.04+7.2%$22.60+87.7%+278.9%$279.57M$80,000.000.0020Analyst ForecastShort Interest ↑ATAIAtai Life Sciences3.01 of 5 stars$1.62+3.5%$9.00+457.3%+4.8%$271.00M$310,000.000.0083Positive NewsLFCRLifecore Biomedical3.6897 of 5 stars$7.33+2.5%$10.00+36.4%+27.7%$269.96M$128.26M89.25690LXEOLexeo Therapeutics3.0409 of 5 stars$8.15+6.8%$23.80+192.0%-44.4%$269.52M$650,000.00-2.4958Positive News Related Companies and Tools Related Companies Q32 Bio Alternatives ProQR Therapeutics Alternatives UroGen Pharma Alternatives Eledon Pharmaceuticals Alternatives Zentalis Pharmaceuticals Alternatives Aclaris Therapeutics Alternatives Benitec Biopharma Alternatives Atai Life Sciences Alternatives Lifecore Biomedical Alternatives Lexeo Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DBVT) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DBV Technologies S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share DBV Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
